Roy C. Cosan

President & Interim Chief Executive Officer at Renova Therapeutics, Inc.

Roy C. Cosan

Roy C. Cosan

President & Interim Chief Executive Officer at Renova Therapeutics, Inc.

Overview
Career Highlights

Orchest Health Corp.
Renova Therapeutics, Inc.
Metronom Health, Inc.

RelSci Relationships

370

Number of Boards

10

Contact Data
Trying to get in touch with Roy C. Cosan? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Roy C. Cosan likely has professional access to. A relationship does not necessarily indicate a personal connection.

Founder, Chief Executive Officer & President at Adagio Medical, Inc.

Relationship likelihood: Strong

Co-Founder at Renova Therapeutics, Inc.

Relationship likelihood: Strong

Co-Founder at Renova Therapeutics, Inc.

Relationship likelihood: Strong

President & Chief Executive Officer at RealBio Technology, Inc.

Relationship likelihood: Strong

Chief Operating Officer & Director at Protostar, Inc.

Relationship likelihood: Strong

President & Chief Executive Officer at Amfora, Inc.

Relationship likelihood: Strong

Operating Executive at Avista Capital Partners

Relationship likelihood: Strong

Chairman of the Board & Chief Executive Officer at Equillium, Inc.

Relationship likelihood: Strong

Principal, Chief Executive Officer & Portfolio Manager at Adelante Capital Management LLC

Relationship likelihood: Strong

Co-Founder at Portage Venture Partners LLC

Relationship likelihood: Strong

Paths to Roy C. Cosan
Potential Connections via
Relationship Science
You
Roy C. Cosan
President & Interim Chief Executive Officer at Renova Therapeutics, Inc.
Education
Undergraduate Degree

Western Michigan University is a national research university enrolling nearly 25,000 students from across the United States and more than 100 other countries. Founded in 1903, it is a learner-centered, discovery-driven and globally engaged public university that stands out among America's more than 5,000 higher education institutions.

Career History
President & Interim Chief Executive Officer
Current

Renova Therapeutics, Inc. operates as a biopharmaceutical company. The firm is developing definitive, one-time gene therapies and peptide infusion treatments to restore the health of people suffering from chronic diseases. Its product, RT-100, is a treatment that delivers a therapeutic gene directly to the heart during a routine outpatient procedure and has the potential to increase heart function in patients with CHF. The company was founded by Jack W. Reich, H. Kirk Hammond and Craig Andrews in 2009 and is headquartered in San Diego, CA.

President
Current

Orchest Health Corp. provides glucose monitoring sensors for diabetes. The company is headquartered in Los Angeles, CA

Professional
Tenure Unconfirmed

RealBio Technology, Inc. develops cell and tissue culture technologies. It introduced D4 Culture System-an advanced, disposable cell culture platform capable of developing full three-dimensional cell structures in vitro. The firm's D4 Culture System enables customers to develop cell structures that mimic the natural composition, configuration and function of normal and diseased tissue. The company was founded by Lee Noll in June 2009 and is headquartered in Kalamazoo, MI.

Boards & Committees
Director
Prior - 2008

Johnson & Johnson Innovation JJDC, Inc. is a venture capital arm of Johnson & Johnson (NYSE: JNJ) located in US. The firm targets companies sectors such as pharmaceuticals, medical devices and consumer healthcare services. They provide financing for all stages, from seed-level startups to Series B and beyond.

Director
Prior - 2006

TorreyPines Therapeutics, formerly Neurogenetics, Inc., was founded in 2000. The company discovers & develops small molecule drugs to treat diseases and disorders of the central nervous system. The company is located in La Jolla, CA

Member, Executive Committee
Prior

ViaCyte, Inc. develops a stem cell-derived islet replacement therapy for the treatment of diabetes. Its development portfolio includes VC-01 product candidate, a cell replacement therapy for the treatment of type 1 diabetes. The company was founded in 1999 and is headquartered in San Diego, CA.

Political Donations
$2,300
2008
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Roy C. Cosan. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Roy C. Cosan's profile does not indicate a business or promotional relationship of any kind between RelSci and Roy C. Cosan.